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Introduction: To facilitate enrollment and meet local registration requirements, sponsors have increasingly
implemented multi-national Alzheimer’s disease (AD) studies. Geographic regions vary on many dimensions that
may affect disease progression or its measurement. To aid researchers designing and implementing Phase 3 AD
trials, we assessed disease progression across geographic regions using placebo data from four large, multi-national
clinical trials of investigational compounds developed to target AD pathophysiology.
Methods: Four similarly-designed 76 to 80 week, randomized, double-blind placebo-controlled trials with nearly
identical entry criteria enrolled patients aged ≥55 years with mild or moderate NINCDS/ADRDA probable AD.
Descriptive analyses were performed for observed mean score and observed mean change in score from baseline
at each scheduled visit. Data included in the analyses were pooled from the intent-to-treat placebo-assigned overall
(mild and moderate) AD dementia populations from all four studies. Disease progression was assessed as change
from baseline for each of 5 scales - the AD Assessment Scale-cognitive subscale (ADAS-cog11), the AD Cooperative
Study- Activities of Daily Living Scale (ADCS-ADL), Mini-Mental State Examination (MMSE), the Clinical Dementia
Rating scored by the sum of boxes method (CDR-SB), and the Neuropsychiatric Inventory (NPI).
Results: Regions were heterogeneous at baseline. At baseline, disease severity as measured by ADAS-cog11,
ADCS-ADL, and CDR-SB was numerically worse for Eastern Europe/Russia compared with other regions. Of
all regional populations, Eastern Europe/Russia showed the greatest cognitive and functional decline from baseline;
Japan, Asia and/or S. America/Mexico showed the least cognitive and functional decline.
Conclusions: These data suggest that in multi-national clinical trials, AD progression or its measurement may differ
across geographic regions; this may be in part due to heterogeneity across populations at baseline. The observed
differences in AD progression between outcome measures across geographic regions may generalize to 'real-world'
clinic populations, where heterogeneity is the norm.
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Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder generally first manifesting as cognitive impairment,
progressing to impairment of daily function and, ultimately,
loss of independence, debility, and death from complicating
medical comorbidities. In the past decade, researchers
have studied treatments that target the underlying patho-
physiology of AD, as yet without approval of any disease-
modifying drug entity. Development of such disease-
modifying therapies is made challenging by the length
and size of studies required to demonstrate positive effects
on co-primary outcome measures of cognition and func-
tion. Most trials have enrolled several hundred to more
than a thousand patients, with studies lasting 12 to 18
months [1]. In order to enroll patients in a reasonable
time period and meet regulatory requirements for local
registration, sponsors have increasingly implemented more
multinational AD studies [2] that cover multiple geographic
regions and encompass many cultures, languages, and
healthcare delivery systems. Multinational AD studies
may be helpful in furthering our understanding of the
effects of a therapy across various standards of care, family
structures, and societal views on outcomes [3].
Despite this trend for large, multinational AD trials,
relatively little is known about the implications of con-
ducting them [3]. There are multiple reasons to expect
heterogeneity in these trials. Making a clinical diagnosis
of AD is challenging and, historically, has occurred by
elimination of other potential etiologies. Even in the
clinical trial setting, 18 to 22% of patients clinically diag-
nosed with AD were found to be lacking evidence of
pathophysiology of AD using amyloid positron emission
tomography tracers [4,5]. Moreover, AD is a complex dis-
ease with multiple risk factors including advancing age,
lower education level, and carrying the ε4 allele of the
apolipoprotein E (APOE) gene as well as other specific
genetic loci [6-10]. Differences in prevalence of risk
factors, variability in clinical diagnosis and differences
related to culture, access to healthcare, and clinical
trial conduct across geographic regions [2] may result
in heterogeneity in patient populations recruited for global
AD trials. Additional factors that could lead to heterogeneity
in multinational AD trials were discussed at a meeting
of representatives from the Alzheimer’s Association, spon-
sors, regulatory bodies, and vendors, and were published
by Doody and colleagues [3]. This heterogeneity has the
potential to result in differences in rates of disease pro-
gression across regions. While differences in dementia
prevalence across geographic regions have been docu-
mented [11], to date there is a paucity of published data
on disease progression across geographic regions.
To aid researchers in designing, implementing, and
analyzing data from multinational phase 3 AD trials, we
assessed disease progression across geographic regionsusing placebo data from four large, multinational clinical
trials of compounds developed to target the underlying
pathophysiology of AD [12,13]. An additional perspective
on AD across geographic regions is provided by Grill and
colleagues [14], who assessed recruitment, retention, and
safety reporting across regions using data from these four
AD trials.
Methods
Placebo data from four randomized double-blind placebo-
controlled AD trials (IDENTITY, IDENTITY2, EXPED-
ITION, EXPEDITION2) were used in this exploratory
analysis. The study designs have been published previously
[12,13,15,16]. Study protocols were reviewed and approved
by the relevant ethical review boards (see Acknowledge-
ments). Briefly, IDENTITY and IDENTITY2 were 76-
week trials designed to study the effect of semagacestat, a
γ-secretase inhibitor no longer in development, on the
progression of AD; EXPEDITION and EXPEDITION2
were 80-week trials designed to study the effect of solane-
zumab, a humanized anti-Aβ peptide antibody currently
in development, on the progression of AD. For each trial,
the research protocol was approved by the ethical review
board at each study site participating in that trial. Written
informed consent for study participation was provided by
the study subject or a legally authorized representative, in
accordance with the Declaration of Helsinki. The current
study analyzing data collected across these clinical trials
was reviewed by the University of California, Los Angeles
(UCLA) Medical Institutional Review Board and deemed
as not meeting the definition of human subjects research.
The entry criteria were nearly identical for the four stud-
ies and included patients 55 years and older with moderate
or mild AD dementia, documented on the basis of a score
of 16 to 19 and of 20 to 26, respectively, on the Mini-
Mental State Examination (MMSE), and meeting criteria
of the National Institute of Neurological and Communica-
tive Diseases and Stroke–Alzheimer’s Disease and Related
Disorders Association for probable AD. Patients with other
etiologies for dementia were to be excluded.
Subjects were required to be medically stable with a
reliable study partner who spent >10 hours per week with
the patient. Subjects were permitted to receive cholinester-
ase inhibitors and/or memantine during the studies but
had to be stable in dose prior to entry and remain stable
during the studies.
Efficacy measures in the four studies included the 11-item
Alzheimer’s Disease Assessment Scale – cognitive subscale
(ADAS-cog11; range 0 to 70, higher scores worse) [17], the
Alzheimer’s Disease Cooperative Study – Activities of Daily
Living Scale (ADCS-ADL; range 0 to 78, lower scores
worse) [18], the Clinical Dementia Rating scored by the
sum of boxes method (CDR-SB; range 0 to 18, higher scores
worse) [19,20], the MMSE (range 0 to 30, lower scores
Henley et al. Alzheimer's Research & Therapy  (2015) 7:43 Page 3 of 10worse) [21], and the Neuropsychiatric Inventory (NPI; range
0 to 144, higher scores worse) [22,23]. Scales were
translated into the native language(s) of the region and
the ADAS-cog11 and ADCS-ADL were administered by
raters trained and qualified in their administration and
scoring. Training without qualification was provided for
all other scales administered in the trials. The protocols
specified that the same rater was to rate the ADAS-cog11
throughout the study and this rater should not rate the
ADCS-ADL. If a rater left a site, both training and
qualification of the new rater was required. Raters falling
below minimal pretrial experience levels in administering
the ADAS-cog were required to complete additional
(enrichment) training and pass a prequalification exam-
ination before undergoing the formal qualification training
and examination at the startup meeting. In addition, if
raters were incorrectly scoring the ADAS-cog11 or MMSE
as determined during instudy rating reviews (performed at
baseline and 52 weeks for the IDENTITY program, and at
baseline and 12 weeks for the EXPEDITION program),
they were contacted and reminded of the correct scoring
algorithm and asked to correct their error(s).
IDENTITY and IDENTITY2 were implemented at 300
sites in 31 countries, with enrollment from April 2008 to
May 2010. EXPEDITION and EXPEDITION2 were im-
plemented at 211 sites in 16 countries, with enrollment
from May 2009 to June 2012. As the result of identifying
an unfavorable benefit/risk ratio with semagacestat in
an interim safety analysis, the IDENTITY studies were
amended to discontinue the study drug and follow study
subjects for an additional 7 months. Only placebo data
from the initial, randomized study period of up to 76
weeks were considered in the present analyses. At the
time at which the IDENTITY protocols were amended,
both studies were fully enrolled with 37.7% and 6.1% of
the IDENTITY and IDENTITY2 study subjects, respect-
ively, having been followed for the full 76-week initial
study period [15]. The EXPEDITION and EXPEDITION2
studies were completed in April 2012 and June 2012 with
73% and 78% of the study populations, respectively, ob-
served for the full 80 weeks.
Statistical analysis
The small sample sizes in most countries (Table 1) necessi-
tated regional instead of by-country analyses. Geographic
regions were defined based on a modified version of cri-
teria used by Glickman and colleagues [24]. Countries were
combined into regions based on ethnicity and healthcare
delivery systems, to increase sample size. Regions were as
follows: North America (United States, Canada); South
America/Mexico (Argentina, Brazil, Chile, Mexico); Western
Europe/Israel (Belgium, Denmark, Finland, France,
Germany, Israel, Italy, Spain, Sweden, United Kingdom);
Eastern Europe/Russia (Bulgaria, Hungary, Poland,Romania, Russia, Serbia, Turkey, Ukraine); Australia/South
Africa; Asia (China, India, Korea, Taiwan); and Japan.
Analyses were performed using SAS version 9.2 (SAS
Institute Inc, Cary, NC). Descriptive analyses were per-
formed for the observed mean score and the observed mean
change in score from baseline at each scheduled visit. Spear-
man’s rank correlations were used to assess the relationship
among AD scales at baseline and among baseline-to-
endpoint (18 months) changes in scores by region. Data
included in the analyses were pooled from the intent-to-
treat placebo-assigned overall (mild and moderate) AD
populations from all four studies. Disease progression
was assessed as the change from baseline for each of the
four scales (ADAS-cog11, ADCS-ADL, MMSE, CDR-SB).
Measurements considered in the analyses were those
performed at baseline and 76/80 weeks (depending on
study), as well as at 12, 28, 40, 52, and 64 weeks for
ADAS-cog11 and ACDS-ADL, 52 weeks for MMSE, and
28 and 52 weeks for CDR-SB.
For the EXPEDITION program, a completer was defined
as a subject who had completed the 80-week double-blind
study period. For the IDENTITY program, a completer was
defined as a subject who had completed the 76-week initial
treatment period; the denominator in this case was the
number of subjects who had an opportunity to complete 76
weeks of treatment before the study drug was stopped at re-
quest of the sponsor and the study was amended.
Results
Enrollment and study completion by region and country
Subject enrollment and completion is shown by country
and region in Table 1. Overall, data from 2,079 subjects
assigned placebo (EXPEDITION, n = 506; EXPEDITION2,
n = 519; IDENTITY, n = 501; IDENTITY2, n = 553) were
included in the analyses. Since the study drug was stopped
before intended study termination in the IDENTITY pro-
gram and the studies were amended, many study subjects
did not have the opportunity to participate until the end-
point visit at 76 weeks. As a result, the IDENTITY pro-
gram had a numerically smaller proportion of completers
than the EXPEDITION program.
Baseline characteristics by region
There were numerical differences in baseline characte-
ristics among regions for these placebo-assigned subjects
(Table 2). The Asia population had the lowest proportion
of subjects with mild disease, defined as MMSE 20 to 26
(42%); generally, subjects were oldest in North America
and South America/Mexico, and youngest in Western
Europe/Israel and Eastern Europe/Russia; subjects had
received the most years of education in North America
and least education in South America/Mexico and Asia;
there were fewer males than females enrolled overall,
but Western Europe/Israel enrolled the highest and South
Table 1 Number of sites, enrolled subjects and subjects completing the study by country and region
Region/country Number of sites Number enrolled Completers, n (%)a
EXPEDITION IDENTITYb
North America 179 832 325 (72) 140 (37)
United States 154 714 286 (71) 127 (41)
Canada 25 118 39 (80) 13 (19)
Western Europe/Israel 112 412 163 (77) 71 (36)
Belgium 4 8 – 5 (63)
Denmark 2 5 – 3 (60)
Finland 3 6 – 6 (100)
France 16 69 23 (92) 9 (20)
Germany 23 104 42 (76) 14 (29)
Israel 7 22 – 8 (36)
Italy 18 74 42 (74) 1 (6)
Spain 16 48 15 (63) 12 (50)
Sweden 12 37 23 (85) 8 (80)
United Kingdom 11 39 18 (72) 5 (36)
South America /Mexico 50 196 82 (75) 8 (9)
Argentina 25 88 43 (67) 0
Brazil 14 67 39 (85) 0
Chile 7 17 – 8 (47)
Mexico 4 24 – 0
Eastern Europe/Russia 49 195 38 (61) 5 (4)
Bulgaria 5 18 – 1 (6)
Hungary 4 16 – 1 (6)
Poland 13 48 24 (67) 3 (25)
Romania 4 17 – 0
Russia 11 45 14 (54) 0
Serbia 3 8 – 0
Turkey 4 23 – 0
Ukraine 5 20 – 0
Japan 46 191 71 (88) 23 (21)
Asia 40 169 59 (84) 0
China 6 22 – 0
India 7 10 – 0
Korea 16 85 33 (79) 0
Taiwan 11 52 26 (93) 0
Australia/South Africa 25 84 32 (84) 18 (39)
Australia 18 58 32 (84) 10 (50)
South Africa 7 26 – 8 (31)
aFor the EXPEDITION program, a completer was defined as a subject who had completed the 80-week double-blind study period. For the IDENTITY program, a
completer was defined as a subject who had completed the 76-week initial treatment period; the denominator in this case was the number of subjects who had
opportunity to complete 76 weeks of treatment before the study drug was stopped at request of the sponsor, and the study was amended.
bSeveral countries were included only in the IDENTITY program (Belgium, Denmark, Finland, Israel, Chile, Mexico, Bulgaria, Hungary, Romania, Serbia, Turkey,
Ukraine, China, India and South Africa).
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proportions of male subjects; while 74 to 94% of subjects
received concomitant AD treatment, it was most commonin Western Europe/Israel and least common in Eastern
Europe/Russia and Australia/South Africa; and APOE ε4
carriers were most common in Western Europe/Israel
Table 2 Baseline characteristics by geographic region
North
America
Western
Europe/Israel
South
America
Eastern
Europe/Russia
Japan Asia Australia/
South Africa
Overall
(n = 832) (n = 412) (n = 196) (n = 195) (n = 191) (n = 169) (n = 84) (N = 2,079)
Study population with mild AD 547 (66%) 265 (64%) 114 (58%) 106 (54%) 132 (69%) 71 (42%) 57 (68%) 1,292 (62%)
Mean (SD) age (years) 75.0 (8.1) 71.6 (7.7) 74.6 (8.0) 70.9 (7.7) 73.1 (7.7) 72.2 (7.7) 73.0 (7.1) 73.4 (8.0)
Mean (SD) education (years) 14.0 (3.1) 11. 2 (4.2) 9.1 (4.5) 11.8 (3.7) 11. 8 (2.8) 9.6 (4.7) 12.2 (3.4) 12.1 (4.1)
Male 381 (45.8%) 205 (49.8%) 66 (33.7%) 70 (35.9%) 73 (38.2%) 68 (40.2%) 38 (45.2%) 901 (43.3%)
AChEI and/or memantine 736 (88.5%) 387 (93.9%) 167 (85.2%) 145 (74.4%) 173 (90.6%) 139 (82.2%) 66 (78.6%) 1,813 (87.2%)
APOE ε4 carriers 481 (63.0%) 218 (65.7%) 96 (51.1%) 90 (51.4%) 98 (53.0%) 39 (42.4%) 51 (61.4%) 1,073 (59.0%)
Mean (SD) baseline scores
ADAS-cog11 21.81 (9.01) 22.97 (9.18) 24.20 (8.75) 27.69 (11.13) 21.37 (6.80) 24.72 (7.72) 21.89 (9.51) 23.02 (9.16)
ADCS-ADL 62.68 (11.66) 59.34 (13.62) 53.72 (14.17) 49.51 (16.91) 60.45 (11.16) 57.02 (4.80) 59.62 (13.04) 59.16 (13.76)
MMSE 21.08 (3.67) 21.10 (3.56) 20.37 (3.07) 20.19 (3.15) 20.75 (3.10) 19.49 (3.57) 20.86 (3.49) 20.77 (3.51)
CDR-SB 5.08 (2.48) 5.41 (2.70) 6.19 (2.74) 7.16 (3.34) 4.95 (2.66) 4.64 (2.53) 5.38 (2.32) 5.41 (2.74)
NPI 9.21 (10.94) 11.03 (11.73) 12.34 (12.82) 11.24 (11.86) 6.70 (8.69) 7.62 (8.68) 12.13 (10.80) 9.81 (11.13)
Data presented as number (%) or mean (standard deviation). AChEI, acetylcholinesterase inhibitor; AD, Alzheimer’s disease; ADAS-cog11, 11-item Alzheimer’s
disease Assessment Scale – cognitive subscale; ADCS-ADL, Alzheimer’s disease Cooperative Study – Activities of Daily Living; APOE, apolipoprotein E; CDR-SB,
Clinical Dementia Rating Scale sum of boxes; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory; SD, standard deviation.
Henley et al. Alzheimer's Research & Therapy  (2015) 7:43 Page 5 of 10and North America and least common in Asia. Baseline
disease severity, as measured by ADAS-cog11, ADCS-
ADL, and CDR-SB, was worse for Eastern Europe/Russia
compared with populations in other regions (Table 3,
Figure 1), but this was not the case for the MMSE and NPI.
Experience with ADAS-cog11 rating by region
Across study programs, enriched training was required
most frequently in Asia and Japan. In IDENTITY, North
America, Western Europe/Israel, Eastern Europe/Russia,
and Australia/South Africa had less need for remedial
training (Table 4); in EXPEDITION, less need for remedial
training was evident in Western Europe/Israel, followed
by North America and Eastern Europe/Russia.
Disease progression by region
Of all regional populations, Eastern Europe/Russia showed
the greatest cognitive and functional decline from base-
line; Japan, Asia, and/or South America/Mexico showed
the least cognitive and functional decline (Table 3,
Figure 1). For ADAS-cog11 specifically, Eastern Europe/
Russia showed the most cognitive decline over the course
of the study (mean change from baseline to 18 months
was 11.0) while Asia and Japan showed the least decline
(mean change from baseline to 18 months was 3.5 and
4.4, respectively); North America, Australia/South Africa,
and Western Europe/Israel showed a similar decline
(mean change from baseline to 18 months was 6.0 to
7.5). In the case of the NPI, the 18-month decline was
greatest for Australia/South Africa, while there was some
improvement in score at 18 months for South America/
Mexico.Correlations between outcome measures by region
Correlations among outcome measures at baseline and
changes in outcome measures from baseline to endpoint
for each region are shown in Figure 2. The range of cor-
relations across regions was generally greater for change
from baseline than at baseline. Scales that include cognitive
assessment (ADAS-cog11 and MMSE) were consistently
well correlated across regions (−0.5 to −0.8); functional
(ADCS-ADL) and global (CDR-SB) assessment scale
scores were also well correlated across regions. For change
from baseline to endpoint, these correlations were gener-
ally lowest for Asia and/or Japan and highest for Eastern
Europe and/or Australia/South Africa. Measures of cogni-
tion (ADAS-cog11 or MMSE) were less correlated with
functional (ADCS-ADL) or global scales (CDR-SB). Corre-
lations between NPI scores and other scale scores were
generally less than 0.5.
Discussion
The objective of this analysis was to better understand
disease progression among geographic regions in the set-
ting of multinational AD clinical trials, based on analysis
of placebo data from the IDENTITY and EXPEDITION
study programs. Although some regions had relatively small
sample sizes (Australia/South Africa, n = 84), differences in
AD progression or its measurement over the trial periods
were evident across regions. Eastern Europe/Russia showed
the greatest cognitive and functional decline from baseline
amongst the regions on the ADAS-cog11 and ADCS ADL
scales (see Table 3), while Asia, Japan, and South America/
Mexico showed the least. The two regions with the largest
study populations, North America and Western Europe/
Table 3 Observed change from baseline to 76/80 weeks by region for outcome measure scores
North
America
Western Europe/
Israel
South
America
Eastern Europe/
Russia
Japan Asia Australia/
South Africa
Overall
(n = 832) (n = 412) (n = 196) (n = 195) (n = 191) (n = 169) (n = 84) (N = 2,079)
ADAS-cog11
6 months 1.62 (5.66) 1.99 (6.12) 0.99 (6.51) 3.06 (7.23) 0.68 (5.04) 0.21 (6.06) 1.64 (5.97) 1.55 (6.00)
12 months 3.88 (7.40) 4.92 (7.76) 3.23 (7.28) 6.53 (9.11) 3.18 (6.57) 1.49 (7.04) 5.44 (8.39) 4.07 (7.62)
18 months 6.04 (9.44) 7.46 (9.68) 4.76 (8.41) 10.95 (10.77) 4.41 (7.99) 3.52 (7.98) 7.3 (11.54) 6.23 (9.48)
ADCS-ADL
6 months −3.2 (7.45) −3.41 (8.90) −1.17 (9.09) −2.07 (8.63) −2.03 (6.78) −2.05 (7.86) −2.29 (9.82) −2.71 (8.12)
12 months −6.26 (10.01) −6.08 (11.08) −3.7 (9.79) −6.39 (12.80) −4.13 (8.76) −4.71 (10.02) −6.18 (13.12) −5.66 (10.51)
18 months −9.16 (12.13) −10.84 (13.44) −5.57 (12.78) −11.51 (14.16) −5.94 (9.39) −7.85 (9.75) −9.00 (14.89) −8.95 (12.48)
MMSE
6 months – – – – – – – –
12 months −2.29 (3.56) −2.14 (3.84) −1.39 (3.49) −3.48 (4.73) −1.79 (3.34) −2.22 (2.92) −2.45 (3.79) −2.21 (3.68)
18 months −3.39 (4.59) −3.66 (4.70) −2.52 (4.18) −5.28 (5.95) −2.78 (4.13) −2.93 (4.06) −3.45 (4.73) −3.38 (4.60)
CDR-SB
6 months 5.77 (3.06) 6.19 (3.24) 6.75 (3.18) 7.59 (3.82) 5.64 (3.31) 5.12 (2.74) 6.25 (3.11) 6.05 (3.24)
12 months 6.47 (3.46) 6.77 (3.67) 7.15 (3.47) 8.74 (4.09) 6.32 (3.71) 5.91 (3.24) 7.45 (3.86) 6.75 (3.64)
18 months 6.98 (3.91) 7.23 (3.98) 7.09 (3.59) 9.72 (4.66) 6.32 (3.92) 6.25 (3.25) 7.90 (4.32) 7.10 (3.96)
NPI
6 months 0.73 (9.52) 0.87 (10.43) 0.00 (11.04) 0.09 (10.79) −0.05 (6.79) 0.71 (9.47) 0.68 (10.73) 0.55 (9.77)
12 months 1.57 (11.15) 0.63 (11.25) 0.81 (13.48) 0.82 (10.88) 2.04 (9.09) 2.02 (12.76) 2.44 (11.46) 1.37 (11.30)
18 months 2.86 (13.36) 2.97 (13.98) −1.80 (14.08) 2.30 (12.57) 2.41 (8.95) 1.83 (10.00) 5.29 (14.11) 2.47 (13.11)
Data presented as mean (standard deviation). ADAS-cog11, 11-item Alzheimer’s disease Assessment Scale – cognitive subscale; ADCS-ADL, Alzheimer’s disease
Cooperative Study – Activities of Daily Living; CDR-SB, Clinical Dementia Rating Scale sum of boxes; MMSE, Mini-Mental State Examination; NPI,
Neuropsychiatric Inventory.
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from baseline on the ADAS-cog11, the 11.0 point increase
for Eastern Europe/Russia was appreciably different from
the regions with the least change from baseline (Asia 3.5
points, Japan 4.4 points). Change from baseline for North
America and Western Europe/Israel, as well as Australia/
South Africa, ranged from 6.0 to 7.5 points.
The differences among geographic regions observed here
may have been the result of heterogeneity in the study popu-
lations across regions. Younger age, female gender, greater
baseline disease severity, absence of treatment with acetyl-
cholinesterase inhibitors and/or memantine, and an APOE
ε4 genotype have been associated with more rapid clinical
disease progression [6,25,26]. The study population of
Eastern Europe/Russia was younger, had a higher pro-
portion of females, and had a lower proportion treated
with AD medications at baseline; baseline outcome meas-
ure scores were also generally more severe for Eastern
Europe/Russia, compared with the other populations.
The proportion of the Eastern European/Russian popu-
lation who were APOE ε4 carriers (51%) as well as the
proportion with mild AD at baseline (54%), however,
lay in the middle of the range across regions. Moredetailed findings on differences/similarities in baseline
characteristics across these geographic regions are pre-
sented by Grill and colleagues, who concluded that popu-
lations recruited in to clinical trials are likely to differ
across regions due to multiple factors – differences in life-
style factors, overall health, access to medical care, stand-
ard of AD diagnosis and treatment, reimbursement for
AD services and treatment, family attitudes toward AD rec-
ognition, reporting of symptoms and research participation,
diagnosis and treatment, and ethnogenetic differences in-
cluding those resulting in different prevalence of APOE ε4
carrier status [14]. Another factor which could contribute
to variability in measurement of disease progression in
these multinational clinical trials is language differences;
although a centralized translation service was used to
minimize the effect of translation on outcomes, this still
does not guarantee equivalence among cultural groups or
regions. Local differences may require slight adjustment
of particular items. For example, in the IDENTITY and
EXPEDITION study programs, orientation to county on
the MMSE had to be adjusted to accept a response of
‘region’ or ‘burro’ where the concept of counties was not
applicable. This may have contributed to some variability
Figure 1 Observed mean score at each time point by region for outcome measure scores. ADAS-cog11, 11-item Alzheimer’s disease
Assessment Scale – cognitive subscale; ADCS-ADL, Alzheimer’s disease Cooperative Study – Activities of Daily Living; CDR-SB, Clinical Dementia Rating
Scale sum of boxes; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory.
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region more readily than county.
Differences in levels of rater experience could also have
contributed to the observed differences in measurement
of AD progression across regions. Yet in these studyTable 4 Requirement for enrichment training for those rating
Trial North America Western Europe/Israel South America
(n = 832) (n = 412) (n = 196)
IDENTITY 26/167 (16) 25/139 (18) 14/39 (36)
EXPEDITION 23/145 (16) 8/90 (9) 7/41 (17)
Data presented as raters in the study who had required enrichment training/tota
Assessment Scale – cognitive subscale.programs, extensive rater training – including enriched
training where necessary and qualification at investigator
meetings – was implemented before raters were permitted
to administer the ADAS-cog11. Miller and colleagues
demonstrated previously that raters who require andADAS-cog11
Eastern Europe/
Russia
Japan Asia Australia/
South Africa
Overall
(n = 195) (n = 191) (n = 169) (n = 84) (N = 2,079)
9/54 (17) 20/48 (42) 14/40 (35) 5/28 (18) 113/515 (22)
4/30 (13) 16/51 (31) 9/23 (39) 9/23 (39) 76/403 (19)
l number of raters in the study (%). ADAS-cog11, 11-item Alzheimer’s disease
Figure 2 (See legend on next page.)
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Figure 2 Correlation between scales by region. (a) Baseline measures. (b) Mean change from baseline to 18 months for study completers.
ADAS-cog11, 11-item Alzheimer’s disease Assessment Scale – cognitive subscale; ADCS-ADL, Alzheimer’s disease Cooperative Study – Activities of
Daily Living; AS, Asia; AU, Australia/South Africa; CDR-SB, Clinical Dementia Rating Scale sum of boxes; EE, Eastern Europe/Russia; JP, Japan. MMSE,
Mini-Mental State Examination; NA, North America; NPI, Neuropsychiatric Inventory; SA, South America/Mexico; WE, Western Europe/Israel.
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similarly to their more experienced colleagues [27].
Therefore, it is unlikely that rater experience alone
could account for the differences in measurement of
AD progression seen in our analyses.
Based on the findings from these analyses, it is prudent
to be mindful of potential regional differences when de-
signing trials, performing analyses, and interpreting find-
ings, so that information collected is of maximum benefit
to all populations who will ultimately have access to the
drug entity, once approved. Differences in AD progression
or its measurement across geographic regions in the clin-
ical trial setting are probably reflective of the real-world
situation where heterogeneity of populations and their
treatments is expected and common. Importantly, in the
IDENTITY and EXPEDITION programs, the regional dif-
ferences did not preclude detection of active drug effects
[12,13]. If a drug effect can be detected within a study
population showing some heterogeneity in disease pro-
gression, the effects are more probably generalizable to
a heterogeneous clinic population.
For these analyses, we also assessed correlations be-
tween scales across regions. Scales that measure cognition
(ADAS-cog11 and MMSE) were consistently well corre-
lated with each other across regions but there was more
variability among regions in correlations between cogni-
tive (ADAS-cog11 or MMSE) and functional (ADCS-
ADL) or global scales (CDR-SB), with some regions show-
ing higher correlations than others. Better understanding
of why this variability occurred will require further study,
but potential differences among cultures in the rele-
vance of functional measures could have contributed
[28]. In addition, the cognitive assessments are performance-
based tests administered to the patient, whereas the
functional scales are proxy report by the caregiver. Since
functional scales are more subjective in nature, these may
be more susceptible to cultural influences, and this may
contribute to regional variability in correlations between
scales.
To our knowledge, this is the first published analysis
assessing AD progression in a clinical trial setting across
geographic regions. Schneider and Sano reviewed data from
11 AD clinical trials of patients with mild-to-moderate
dementia, conducted both in the United States and out-
side the United States, but did not perform regional ana-
lyses [1]. Overall, for these 11 studies the 18-month mean
change from baseline on ADAS-cog11 ranged from
4.34 to 9.10 (standard deviation 8.2 to 9.4); analysismethodology did differ across the studies. In the present
analyses, overall findings were similar, with an 18-month
mean change in ADAS-cog11 of 6.23 (standard deviation
9.48).
There are limitations to these analyses. Geographic
groupings – while based on those of Glickman and col-
leagues [24] and expected similarities in environmental
factors (for example, healthcare, culture) across coun-
tries within regions – may be somewhat arbitrary, and
heterogeneity within regions is likely. Analysis by coun-
try would have reduced this effect to some degree, but
sample sizes were generally small at the country level,
limiting the interpretability of findings. In some countries,
patients were enrolled only in IDENTITY, a program in
which the study drug was stopped due to an unfavorable
benefit/risk ratio for active drug (semagacestat). As a
result, the proportion of study completers in these
IDENTITY-only countries was small. Despite grouping
countries into regions, the sample size limitation remained
to some extent and we performed descriptive analyses ra-
ther than formal comparisons across regions.
Conclusion
These data suggest that AD progression or its measure-
ment may differ across geographic regions in multinational
clinical trials; this may be in part due to heterogeneity
across populations at baseline. The observed differences in
AD progression and correlations between outcome mea-
sures across the geographic regions may be reflective of the
real-world situation, where heterogeneity of populations
and their treatments is expected and common. Trial spon-
sors will need to continue to implement multinational
studies due to required study sizes, enrollment rates, and
regulatory requirements; these data will be helpful in study
planning.
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